US 11,986,558 B2
Drug delivery system
Achim Schneeberger, Vienna (AT); Klaus Kühne, Berlin (DE); Helmut Kerschbaumer, Zürich (CH); and Srdan Vasic, Horgen (CH)
Assigned to Laxxon Medical AG, Stetten (CH); and Exentis Knowledge GmbH, Stetten (CH)
Filed by Laxxon Medical AG, Stetten (CH); and Exentis Knowledge GmbH, Stetten (CH)
Filed on Jul. 13, 2022, as Appl. No. 17/863,884.
Application 17/863,884 is a division of application No. 16/958,777, granted, now 11,419,824, previously published as PCT/EP2017/084825, filed on Dec. 29, 2017.
Prior Publication US 2022/0339109 A1, Oct. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/20 (2006.01); A61K 31/422 (2006.01); A61K 31/44 (2006.01); A61K 31/4439 (2006.01); A61K 31/4468 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/7072 (2006.01)
CPC A61K 9/2077 (2013.01) [A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 31/422 (2013.01); A61K 31/44 (2013.01); A61K 31/4439 (2013.01); A61K 31/4468 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/7072 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A drug delivery system for a controlled administration of an active pharmaceutical ingredient, API, to a body, the system comprising:
a base component soluble in body fluids,
a separate first component soluble in body fluids, and
a separate second component soluble in body fluids,
wherein the first component comprises a therapeutically effective amount of a first API,
wherein the second component comprises a therapeutically effective amount of a second API,
wherein the first component and the second component are inhomogeneously arranged in the base component,
wherein the first component or a separate marking component is optically different from the base component and arranged such that it forms a two-dimensional pattern on the surface of the system.